Modern is consistent with the literature in this space, but the trial shows that a staged complete procedure might be just ...

Having more-thorough workup uncovered an unexpected root cause and changed the treatment course for 76% of patients.

The saphenous vein grafts treated in the RCT were relatively straightforward, while the native vessels were largely CTOs.

The intracoronary fibrinolysis infusion joins a host of other failed treatments to improve microvascular obstruction after ...

Sahil Parikh and David Cohen discuss the late-breaking trials from day 3.

Operators are excited about a device that avoids transapical access, a limitation of other systems, says Gilbert Tang.

The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.

The device, which is delivered transapically, represents an option for very sick patients who previously have had none.

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Mamas Mamas, Christian Spaulding, and Simon Ecclehsall discuss the one-year results of the SELUTION DeNovo Trial.

The DCB is meant to address long-term stent-related complications and avoid adding yet another metal layer in ISR.